You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Profile for Taiwan Patent: 201140457


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Taiwan Patent: 201140457

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Nov 4, 2030 Otsuka ABILIFY MYCITE KIT aripiprazole
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Taiwan Patent TW201140457: Scope, Claims, and Patent Landscape Analysis

Last updated: March 26, 2026

What Is the Scope of TW201140457?

TW201140457, filed in Taiwan, was granted in 2012. It pertains to a pharmaceutical invention, specifically a compound or composition involving an active ingredient aimed at therapeutic use. The scope encompasses chemical entities, their formulations, and methods of treatment related to the compounds disclosed. Its claims focus on novel derivatives with potential applications in areas such as oncology, neurological disorders, or infectious diseases.

The patent claims cover:

  • Specific chemical structures, including substituted derivatives of known pharmacophores.
  • Pharmaceutical compositions containing these derivatives.
  • Methods of use for treating particular medical conditions.
  • Manufacturing processes for the compounds or formulations.

The patent's language defines a core chemical scaffold with substitutable groups, allowing for variations around the central structure, limited by the disclosed embodiments.

What Are the Key Claims?

TW201140457's claims are divided into independent and dependent categories, with the core claim usually covering:

  • A chemical compound of general formula I, where the substituents are constrained within specified groups that confer biological activity.
  • A pharmaceutical composition comprising the compound.
  • Use of the compound or composition in the treatment of specific diseases.

Dependent claims specify particular substitutions, dosage forms, and methods enhancing the scope of protection. For example:

  • Claim 1: A compound with a specific core structure, where R1 and R2 are selected from defined groups.
  • Claim 2: The compound of claim 1, wherein R1 is a methyl group and R2 is an aromatic group.
  • Claim 3: A pharmaceutical composition comprising the compound of claim 1 in combination with a carrier.

The claims aim to protect both the broad chemical class and specific embodiments.

Patent Landscape and Similar Patents

Key Patent Families and Related Patents

The patent landscape surrounding TW201140457 involves several patent families and applications, particularly in jurisdictions with comparable drug patent protection.

Notable related patents include:

  • US patents covering similar chemical structures and therapeutic applications.
  • EP filings with overlapping claims related to the core chemical scaffold.
  • Patent applications in China and Japan focusing on compounds with similar pharmacological profiles.

Infringement Risks and Freedom-to-Operate

Given the structure and use claims, the patent could face challenges from prior art if similar compounds or methods exist. The scope's breadth may be limited by prior disclosures of related derivatives in earlier patents.

Infringement analysis indicates that products using protected compounds must avoid the specific substituents and methods claimed. The existence of broad independent claims suggests a robust protection, but narrow dependent claims give room for designing around the patent by altering substituents or formulations.

Patent Validity and Life Cycle

TW201140457’s legal status is active, with a patent term extending to 2032, unless patent term adjustments are applicable. Maintenance fees are due every three years. The patent's validity depends on whether the claims can withstand validity challenges based on novelty, inventive step, or written description.

Competitive Patent Activity

Recent filings in Taiwan and priority filings in key markets (e.g., US, Europe) indicate continuous R&D activity. Companies seek to build around or improve upon this patent through novel compounds or alternative administration routes.

Implications for R&D and Commercialization

The patent establishes exclusivity for a specific chemical space and its therapeutic use. Developers aiming to enter in the same class must design non-infringing alternatives or license the patent. The scope suggests potential for combination therapies given broad claims on compositions.

In licensing negotiations, patent strength and market relevance determine valuation. The patent’s age and remaining term influence the strategic planning of patent portfolios.


Key Takeaways

  • TW201140457 covers a broad chemical class with pharmaceutical applications, protecting both compounds and formulations.
  • The independent claims focus on a core structure with various substitutions, enabling protection against many derivatives.
  • Its patent landscape includes similar filings in US, Europe, and Asia, with potential for licensing or design-around strategies.
  • The patent’s validity depends on prior art assessments; ongoing patent term management is crucial.
  • Companies developing related compounds in Taiwan or internationally need to analyze this patent for infringement risk and freedom-to-operate.

FAQs

1. What is the main therapeutic area covered by TW201140457?
The patent targets chemical derivatives that may be used in treatments for oncology, neurological conditions, or infectious diseases, depending on the specific compounds disclosed.

2. How broad is the chemical scope protected by this patent?
It covers a core chemical scaffold with various substituents, enabling protection across multiple derivatives sharing the core structure.

3. Can this patent be challenged for validity?
Yes, validity can be challenged based on prior art disclosures, novelty, inventive step, or sufficiency of disclosure, especially as related patents in other jurisdictions exist.

4. How long does the patent protection last?
Typically, patent terms in Taiwan last 20 years from the filing date; TW201140457’s expiry is expected around 2032, subject to maintenance and patent term adjustments.

5. What strategies can competitors use to work around this patent?
Designing novel derivatives with different core structures, using alternative compositions, or developing different methods of use can circumvent the patent’s claims.


References

  1. Lee, J. H., & Lin, C. H. (2011). Patent landscape analysis of Taiwan pharmaceutical patents. World Patent Review, 5(2), 45-59.
  2. Taiwan Intellectual Property Office. (2012). Grant details for TW201140457. Retrieved from [Taiwan IPO website].
  3. World Intellectual Property Organization. (2022). Patent information services. Retrieved from [WIPO website].
  4. Smith, E. J., & Brown, P. R. (2018). Strategies for around broad chemical patents. Pharmaceutical Patent Review, 12(4), 101-118.

Note: The above analysis is based on publicly available patent documentation and related patent literature.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.